SkinBioTherapeutics PLC
LSE:SBTX

Watchlist Manager
SkinBioTherapeutics PLC Logo
SkinBioTherapeutics PLC
LSE:SBTX
Watchlist
Price: 12.625 GBX 3.06%
Market Cap: 32.7m GBX

SkinBioTherapeutics PLC
Capital Expenditures

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

SkinBioTherapeutics PLC
Capital Expenditures Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
SkinBioTherapeutics PLC
LSE:SBTX
Capital Expenditures
-ÂŁ158.8k
CAGR 3-Years
-18%
CAGR 5-Years
-17%
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Capital Expenditures
-$34k
CAGR 3-Years
44%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Capital Expenditures
-$2.1m
CAGR 3-Years
51%
CAGR 5-Years
-14%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Capital Expenditures
-ÂŁ5.2m
CAGR 3-Years
-72%
CAGR 5-Years
-4%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Capital Expenditures
-ÂŁ18.6m
CAGR 3-Years
34%
CAGR 5-Years
9%
CAGR 10-Years
-2%
Oxford BioMedica PLC
LSE:OXB
Capital Expenditures
-ÂŁ4.2m
CAGR 3-Years
29%
CAGR 5-Years
24%
CAGR 10-Years
8%
No Stocks Found

SkinBioTherapeutics PLC
Glance View

Market Cap
32.7m GBX
Industry
Biotechnology

SkinBioTherapeutics Plc is a life science company, which focuses on skin health. The company is headquartered in Macclesfield, Cheshire and currently employs 7 full-time employees. The company went IPO on 2017-04-05. The firm is targeting a number of skin healthcare sectors, which are cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin axis, medical device applications and others. The Company’s platform technology, SkinBiotix, is designed to promote skin health by harnessing the beneficial properties of probiotic bacteria and the active components derived from them. SkinBiotix protects the skin from infection and increases the rate of skin healing in response to injury. The firm's AxisBiotix technology is based on the emerging area of science that is focused on the gut-skin axis and the constitution of the gut microbiome plays a role in various diseases, such as psoriasis. AxisBiotix-Ps is the product developed by the Company that uses the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis.

SBTX Intrinsic Value
15.812 GBX
Undervaluation 20%
Intrinsic Value
Price

See Also

What is SkinBioTherapeutics PLC's Capital Expenditures?
Capital Expenditures
-158.8k GBP

Based on the financial report for Jun 30, 2025, SkinBioTherapeutics PLC's Capital Expenditures amounts to -158.8k GBP.

What is SkinBioTherapeutics PLC's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
-17%

Over the last year, the Capital Expenditures growth was 20%. The average annual Capital Expenditures growth rates for SkinBioTherapeutics PLC have been -18% over the past three years , -17% over the past five years .

Back to Top